Product Description
FOLFOX is the most common chemotherapy combination prescribed in colorectal cancer. It is composed of calcium levofolinate, 5-fluorouracil and oxaliplatin which demonstrated synergistic outcome. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34053358/)
Mechanisms of Action: Folic Acid Analogue
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Belgium | Denmark | France | Japan | Portugal | Spain | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: AZIENDA OSPEDALIERAN CAMILLO FORLANINI
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Italy
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2024-513376-17-00 | P2 |
Unknown Status |
Colorectal Cancer |
2026-05-29 |
|
PRIME-RT | P2 |
Unknown status |
Colorectal Cancer |
2025-10-02 |